Basilea submits Toctino MAA to 15 additional European countries

Swiss drugmaker Basilea Pharmaceutica has submitted a Marketing Authorization Application for Toctino (alitretinoin) in 13  additional European Union member states, as well as in Norway and  Iceland. The agent is a new, once-daily oral treatment for adults with  severe chronic hand eczema unresponsive to potent topical  corticosteroids. The MAA for Toctino was submitted under the Repeat Use  Procedure. "Our submission in 15 additional European countries is a key  step towards this goal," said Anthony Man, chief executive of Basilea.  "Furthermore, pending local approval of this second wave of Marketing  Authorization Applications, we are exploring options for  third-party distribution of this innovative medicine in some of these  countries," he added.